Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Identifieur interne : 003085 ( PubMed/Curation ); précédent : 003084; suivant : 003086Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Auteurs : Albert Marchetti [États-Unis] ; Raf Magar ; Leslie Findley ; Jan P. Larsen ; Zvezdan Pirtosek ; Evzen Růzicka ; Evzen R Uzizka ; Robert Jech ; Jaroslaw Sławek ; Fayyaz AhmedSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Aged, Blepharospasm (drug therapy), Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Dose-Response Relationship, Drug, Europe (epidemiology), Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Retrospective Studies, Severity of Illness Index, Time Factors, Torticollis (drug therapy), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- geographic , epidemiology : Europe.
- drug therapy : Blepharospasm, Torticollis.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- Adult, Aged, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
The purpose of this study is to evaluate the real-world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty-one percent of patients fell into the Dysport-to-BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport-to-BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose-conversion factors are not applicable.
DOI: 10.1002/mds.20468
PubMed: 15810022
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003085
Links to Exploration step
pubmed:15810022Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.</title><author><name sortKey="Marchetti, Albert" sort="Marchetti, Albert" uniqKey="Marchetti A" first="Albert" last="Marchetti">Albert Marchetti</name><affiliation wicri:level="1"><nlm:affiliation>Thomson Health Economics Research, Secaucus, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Thomson Health Economics Research, Secaucus, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Magar, Raf" sort="Magar, Raf" uniqKey="Magar R" first="Raf" last="Magar">Raf Magar</name></author><author><name sortKey="Findley, Leslie" sort="Findley, Leslie" uniqKey="Findley L" first="Leslie" last="Findley">Leslie Findley</name></author><author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P" last="Larsen">Jan P. Larsen</name></author><author><name sortKey="Pirtosek, Zvezdan" sort="Pirtosek, Zvezdan" uniqKey="Pirtosek Z" first="Zvezdan" last="Pirtosek">Zvezdan Pirtosek</name></author><author><name sortKey="Ruzicka, Evzen" sort="Ruzicka, Evzen" uniqKey="Ruzicka E" first="Evzen" last="Růzicka">Evzen Růzicka</name></author><author><name sortKey="R Uzizka, Evzen" sort="R Uzizka, Evzen" uniqKey="R Uzizka E" first="Evzen" last="R Uzizka">Evzen R Uzizka</name></author><author><name sortKey="Jech, Robert" sort="Jech, Robert" uniqKey="Jech R" first="Robert" last="Jech">Robert Jech</name></author><author><name sortKey="Slawek, Jaroslaw" sort="Slawek, Jaroslaw" uniqKey="Slawek J" first="Jaroslaw" last="Sławek">Jaroslaw Sławek</name></author><author><name sortKey="Ahmed, Fayyaz" sort="Ahmed, Fayyaz" uniqKey="Ahmed F" first="Fayyaz" last="Ahmed">Fayyaz Ahmed</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20468</idno><idno type="RBID">pubmed:15810022</idno><idno type="pmid">15810022</idno><idno type="wicri:Area/PubMed/Corpus">003085</idno><idno type="wicri:Area/PubMed/Curation">003085</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.</title><author><name sortKey="Marchetti, Albert" sort="Marchetti, Albert" uniqKey="Marchetti A" first="Albert" last="Marchetti">Albert Marchetti</name><affiliation wicri:level="1"><nlm:affiliation>Thomson Health Economics Research, Secaucus, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Thomson Health Economics Research, Secaucus, New Jersey</wicri:regionArea></affiliation></author><author><name sortKey="Magar, Raf" sort="Magar, Raf" uniqKey="Magar R" first="Raf" last="Magar">Raf Magar</name></author><author><name sortKey="Findley, Leslie" sort="Findley, Leslie" uniqKey="Findley L" first="Leslie" last="Findley">Leslie Findley</name></author><author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P" last="Larsen">Jan P. Larsen</name></author><author><name sortKey="Pirtosek, Zvezdan" sort="Pirtosek, Zvezdan" uniqKey="Pirtosek Z" first="Zvezdan" last="Pirtosek">Zvezdan Pirtosek</name></author><author><name sortKey="Ruzicka, Evzen" sort="Ruzicka, Evzen" uniqKey="Ruzicka E" first="Evzen" last="Růzicka">Evzen Růzicka</name></author><author><name sortKey="R Uzizka, Evzen" sort="R Uzizka, Evzen" uniqKey="R Uzizka E" first="Evzen" last="R Uzizka">Evzen R Uzizka</name></author><author><name sortKey="Jech, Robert" sort="Jech, Robert" uniqKey="Jech R" first="Robert" last="Jech">Robert Jech</name></author><author><name sortKey="Slawek, Jaroslaw" sort="Slawek, Jaroslaw" uniqKey="Slawek J" first="Jaroslaw" last="Sławek">Jaroslaw Sławek</name></author><author><name sortKey="Ahmed, Fayyaz" sort="Ahmed, Fayyaz" uniqKey="Ahmed F" first="Fayyaz" last="Ahmed">Fayyaz Ahmed</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Blepharospasm (drug therapy)</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Europe (epidemiology)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuromuscular Agents (administration & dosage)</term><term>Neuromuscular Agents (therapeutic use)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Torticollis (drug therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term><term>Torticollis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study is to evaluate the real-world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty-one percent of patients fell into the Dysport-to-BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport-to-BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose-conversion factors are not applicable.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15810022</PMID><DateCreated><Year>2005</Year><Month>08</Month><Day>04</Day></DateCreated><DateCompleted><Year>2005</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.</ArticleTitle><Pagination><MedlinePgn>937-44</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this study is to evaluate the real-world dose utilization of Dysport and BOTOX for cervical dystonia and blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted utilization data for patients who received Dysport before switching to BOTOX or BOTOX before switching to Dysport. Patients were identified during scheduled clinic visits and selected if they met study criteria, which included treatment for at least 2 consecutive years (at least 1 year with Dysport or BOTOX, then switched and maintained on BOTOX or Dysport for at least another year). A total of 114 patients were included in the assessment. Ratios of mean dose for Dysport to BOTOX ranged from a low of 2:1 to a high of 11:1. Thirty-one percent of patients fell into the Dysport-to-BOTOX ratio grouping of 5:1 to less than 6:1; 30% of patients had a mean ratio of Dysport to BOTOX of 4:1 to less than 5:1; and only 21% of all patients evaluated fell into the Dysport-to-BOTOX ratio grouping of 3:1 to less than 4:1. Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose-conversion factors are not applicable.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Thomson Health Economics Research, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magar</LastName><ForeName>Raf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Findley</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Jan P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Pirtosek</LastName><ForeName>Zvezdan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Růzicka</LastName><ForeName>Evzen</ForeName><Initials>E</Initials></Author><Author ValidYN="N"><LastName>Råuzizka</LastName><ForeName>Evzen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jech</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sławek</LastName><ForeName>Jaroslaw</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Fayyaz</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2006 Apr;21(4):582-3; author reply 583-4</RefSource><PMID Version="1">16511854</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Mov Disord. 2005 Aug;20(8):1089</RefSource><Note>Råuzizka, Evzen [corrected to Růzicka, Evzen]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001764">Blepharospasm</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005060">Europe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014103">Torticollis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20468</ArticleId><ArticleId IdType="pubmed">15810022</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003085 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003085 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15810022
|texte= Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15810022" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |